Technologies

Transformative, Interventional Technologies

With an infinite mindset and holistic understanding of chronic eye diseases, we are dedicated to developing and commercializing less invasive technologies. We focus on targeting the underlying diseases and empowering eyecare providers to intervene earlier in disease progression.

OMNI

OMNI® Delivers the Ultimate Experience in Interventional Glaucoma

Engineered Precision. Comprehensive Intervention. Proven Performance.

The OMNI Surgical System enables a comprehensive, implant-free MIGS procedure that reduces intraocular pressure by addressing three areas of resistance in the aqueous outflow system—the trabecular meshwork, Schlemm’s canal, and the collector channels. Adaptable to all stages of primary open-angle glaucoma, OMNI can be performed as a standalone procedure or combined with cataract surgery.

OMNI® Edge with TruSync™ technology enables surgeons to dispense up to 21 µL of viscoelastic with precise control, while maintaining the trusted ergonomics, safety, and versatility of the OMNI Surgical System. TruSync™ is a patented viscoelastic delivery technology synchronized with surgeon rotation of the control wheel — enabling consistent, predictable, and reproducible viscoelastic deployment along every treated clock hour of Schlemm’s canal.

LEARN MORE

Important Product Information

Instructions for Use

Procedure Guide

Device Sales Aid

Reimbursement Guide

OMNI® Surgical System with TruSync™ technology is a handheld, single-use device for minimally invasive glaucoma surgery. It delivers up to 11 µL of viscoelastic and provides 360-degree access to the eye’s conventional outflow system through a single clear corneal microincision.

omni product

LEARN MORE

Explore OMNI

Important Product Information

Instructions for Use

Procedure Guide

Device Sales Aid

Sion

Goniotomy Elevated

With a bladeless tip designed to facilitate a smooth, gentle goniotomy

Explore SION

Important Product Information

sion product

Tearcare

A Better Approach for Treating DED

Smart. Convenient. Long-lasting.

The unique features of the TearCare® System allow ECPs and their patients to experience an MGD treatment like no other.

Explore TearCare

Important Product Information

Tearcare product

Want to speak to one of our representatives?

Contact Us

Important Product Information

OMNI® Surgical System

Indications for Use

The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

Contraindications

Do not use the OMNI in any situations where the iridocorneal angle is compromised or has been damaged (e.g., from trauma or surgery), since it may not be possible to visualize the angle or to properly pass the microcatheter.
Do not use the OMNI in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris.
Do not use the OMNI Surgical System in quadrants with previous MIGS implants.
Please refer to the full Instructions for Use, available below, for warnings, precautions, and adverse event information.

Warnings

Do not use in cases where there is insufficient visibility to properly see the iridocorneal angle. The following conditions may prohibit sufficient visualization required for safe and successful cannula and microcatheter placement: corneal edema, corneal haze, corneal opacity, or any other conditions that may inhibit gonioscopic view of the iridocorneal angle and intended cannula entry location.
Perform gonioscopy prior to taking a patient to surgery to exclude congenital anomalies of the iridocorneal angle, anterior segment dysgeneses, peripheral anterior synechiae (PAS), rubeosis, and any other angle abnormalities that could lead to improper placement of the cannula and microcatheter and pose a hazard.
Maintain direct microscopic or gonioscopic visualization of the cannula tip and microcatheter tip at all times during the procedure to facilitate advancement and to avoid inadvertently damaging intraocular structures, kinking the microcatheter or unintended tearing of trabecular meshwork.
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. If intraocular pressure is not adequately maintained after surgery, the surgeon should initiate appropriate management of intraocular pressure.

Potential adverse events

Adverse events that may be reasonably associated with the use of the OMNI® System in the eye include, but are not limited to, the following: anterior chamber shallowing, severe, prolonged, or persistent intraocular inflammation, endophthalmitis or other ocular infection, aqueous misdirection, Descemet’s membrane tear or detachment, intracorneal hematoma, choroidal effusion, suprachoroidal hemorrhage, corneal decompensation, corneal injury, corneal edema or opacification, unintended trabeculotomy, cyclodialysis cleft, hyphema, hypopyon, hypotony, hypotony maculopathy, IOL dislocation, cataract formation, iris injury, tear, or iridodialysis, loss of vitreous, perforation of sclera, posterior capsular bag rupture, proliferative vitreoretinopathy, pupillary block, pupillary membrane formation, retinal detachment, retinal dialysis, retinal flap tears, secondary surgical intervention, including, but not limited to, glaucoma surgery, and vitreous hemorrhage. Federal (USA) law restricts this device to sale, distribution, or use by or on the order of a physician.

Full Instructions for Use

Important Product Information

OMNI® Edge Surgical System

Indications for Use

The OMNI® Edge Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

Contraindications

Do not use the OMNI in any situations where the iridocorneal angle is compromised or has been damaged (e.g., from trauma or surgery), since it may not be possible to visualize the angle or to properly pass the microcatheter.
Do not use the OMNI in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris.
Do not use the OMNI Surgical System in quadrants with previous MIGS implants.
Please refer to the full Instructions for Use, available below, for warnings, precautions, and adverse event information.

Warnings

Do not use in cases where there is insufficient visibility to properly see the iridocorneal angle. The following conditions may prohibit sufficient visualization required for safe and successful cannula and microcatheter placement: corneal edema, corneal haze, corneal opacity, or any other conditions that may inhibit gonioscopic view of the iridocorneal angle and intended cannula entry location.
Perform gonioscopy prior to taking a patient to surgery to exclude congenital anomalies of the iridocorneal angle, anterior segment dysgeneses, peripheral anterior synechiae (PAS), rubeosis, and any other angle abnormalities that could lead to improper placement of the cannula and microcatheter and pose a hazard.
Maintain direct microscopic or gonioscopic visualization of the cannula tip and microcatheter tip at all times during the procedure to facilitate advancement and to avoid inadvertently damaging intraocular structures, kinking the microcatheter or unintended tearing of trabecular meshwork.
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. If intraocular pressure is not adequately maintained after surgery, the surgeon should initiate appropriate management of intraocular pressure.

Potential adverse events

Adverse events that may be reasonably associated with the use of the OMNI® System in the eye include, but are not limited to, the following: anterior chamber shallowing, severe, prolonged, or persistent intraocular inflammation, endophthalmitis or other ocular infection, aqueous misdirection, Descemet’s membrane tear or detachment, intracorneal hematoma, choroidal effusion, suprachoroidal hemorrhage, corneal decompensation, corneal injury, corneal edema or opacification, unintended trabeculotomy, cyclodialysis cleft, hyphema, hypopyon, hypotony, hypotony maculopathy, IOL dislocation, cataract formation, iris injury, tear, or iridodialysis, loss of vitreous, perforation of sclera, posterior capsular bag rupture, proliferative vitreoretinopathy, pupillary block, pupillary membrane formation, retinal detachment, retinal dialysis, retinal flap tears, secondary surgical intervention, including, but not limited to, glaucoma surgery, and vitreous hemorrhage. Federal (USA) law restricts this device to sale, distribution, or use by or on the order of a physician.

Full Instructions for Use

Important Product Information

TearCare® System

Indications for Use

The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.

Contraindications

The TearCare® System is contraindicated for patients with:

Recent (i.e. within the last 90 days) surgical procedure to the eye or eyelid.
Recent ocular injury.
History of Herpes Simplex or Herpes Zoster of the eye or eyelid.
Active ocular or periocular infection, inflammation or irritation.
Diminished or abnormal facial, periocular, ocular, or corneal sensation.
Ocular surface ulcers.
Hordeolum, stye, or chalazion.
Do not use the TearCare® System in patients under the age of 22 years.
Pacemakers or implantable cardiac defibrillators (ICD). Use of the TearCare® System may affect the performance of pacemakers or ICD’s due to electromagnetic interference (EMI). To avoid any potentially serious safety effects, patients with these implants should not be treated with the TearCare® System.
Known allergy to acrylate.
Known allergy to silicone tissue adhesives.
Known allergy to copper.

Warnings

Do not use the TearCare® System outside the instructions for use. Doing so can result in unanticipated patient harm.
Do not attempt to connect the SmartHub™ or SmartLid™ directly to an electrical outlet of any kind.
Do not use the TearCare® System in or near an MRI suite or near a magnetic field. Serious injury can occur to a patient or technician if a TearCare®System is brought into an MRI suite.
The TearCare® System has not been tested in the presence of flammable anesthetics or other flammable agents in combination with air, nitrous oxide, or oxygen enriched environments.
Do not apply SmartLids to non-intact skin (i.e., skin with active abrasion, cut, burn, rash, inflammation, redness, etc.)

Precautions

Use of the TearCare® System in patients with eyelid abnormalities (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severeptosis, etc.) may result in poor adhesion of the SmartLid™ to the eyelid and/or reduced benefit.
Use caution when using the TearCare® System in patients with ocular surface abnormalities (e.g. pterygium, pingueculum, corneal dystrophies, etc.) as the heat delivered by the System may aggravate these conditions.
Remove contact lenses from the patient’s eyes prior to use of the TearCare® System. Patients should wait 60 minutes after the completion of the TearCare® procedure before re-inserting contact lenses.
Do not apply the SmartLids™ to any other part of the patient’s body including the cornea. The SmartLids™ are only intended for application on the external surface of the patient’s eyelids.
It is important for patient to keep their eyes open (blinking is permitted) during treatment, to allow heat to dissipate off of the ocular surface.
Effectiveness of the TearCare®System has not been established in subjects for whom the treatment temperature is lowered from Warmth Level Setting #5 due to patient pain or discomfort.
Do not reuse the SmartLids™. Cross-contamination can occur if re-use is attempted.
Do not use a TearCare® System, its components, or accessories that appear damaged. Inspect all components for damage before each use.
The safety and effectiveness of the TearCare®System is not known in the following patient populations that were excluded in the OLYMPIA pivotal study: patients under 22 years of age, dry eye signs and symptoms other than meibomian gland dysfunction, severe signs and symptoms of dry eye due to meibomian gland dysfunction (OSDI > 79), mild signs and symptoms of dry eye due to meibomian gland dysfunction, and other study exclusions described in the TearCare®Instructions for Use.

POTENTIAL ADVERSE EVENTS

Potential adverse events may include but are not limited to:

Eyelid or eye pain requiring discontinuation of the treatment procedure
Eyelid irritation or inflammation*
Ocular surface irritation or inflammation*
Ocular symptoms (such as burning, redness, tearing, visual disturbance, redness)
Burn, erythema, or swelling of the eyelids
Conjunctival infection (moderate or severe)
Conjunctival abrasion
Corneal abrasion
Corneal deformation
Allergic or inflammatory reaction to medical adhesive on the SmartLid device
Formation of a chalazion or stye*
Decline in visual acuity*
Worsening of dry eye symptoms*
Increased discomfort or pain of ocular surface (grittiness, foreign body sensation, etc.)
Discomfort or pain of eyelids or orbit*
There is a potential risk of thermal injury to eye or eyelid based on the device design.

Full Instructions for Use

Important Product Information

INDICATIONS FOR USE

The TearCare^® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.

CONTRAINDICATIONS

^®

Recent (i.e. within the last 90 days) surgical procedure to the eye or eyelid.
Recent ocular injury.
History of Herpes Simplex or Herpes Zoster of the eye or eyelid.
Active ocular or periocular infection, inflammation or irritation.
Diminished or abnormal facial, periocular, ocular, or corneal sensation.
Ocular surface ulcers.
Hordeolum, stye, or chalazion.
Do not use the TearCare® System in patients under the age of 22 years.
Pacemakers or implantable cardiac defibrillators (ICD). Use of the TearCare® System may affect the performance of pacemakers or ICD’s due to electromagnetic interference (EMI). To avoid any potentially serious safety effects, patients with these implants should not be treated with the TearCare^® System.
Known allergy to acrylate.
Known allergy to silicone tissue adhesives.
Known allergy to copper.

WARNINGS

Do not use the TearCare^® System outside the instructions for use. Doing so can result in unanticipated patient harm.
Do not attempt to connect the SmartHub^™ or SmartLid^™ directly to an electrical outlet of any kind.
Do not use the TearCare^® System in or near an MRI suite or near a magnetic field. Serious injury can occur to a patient or technician if a TearCare^® System is brought into an MRI suite.
The TearCare^® System has not been tested in the presence of flammable anesthetics or other flammable agents in combination with air, nitrous oxide, or oxygen enriched environments.
Do not apply SmartLids to non-intact skin (i.e., skin with active abrasion, cut, burn, rash, inflammation, redness, etc.)

PRECAUTIONS

Use of the TearCare^® System in patients with eyelid abnormalities (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis, etc.) may result in poor adhesion of the SmartLid^™ to the eyelid and/or reduced benefit.
Use caution when using the TearCare^® System in patients with ocular surface abnormalities (e.g. pterygium, pingueculum, corneal dystrophies, etc.) as the heat delivered by the System may aggravate these conditions.
Remove contact lenses from the patient’s eyes prior to use of the TearCare^® System. Patients should wait 60 minutes after the completion of the TearCare^® procedure before re-inserting contact lenses.
Do not apply the SmartLids^™ to any other part of the patient’s body including the cornea. The SmartLids^™ are only intended for application on the external surface of the patient’s eyelids.
It is important for patient to keep their eyes open (blinking is permitted) during treatment, to allow heat to dissipate off of the ocular surface.
Effectiveness of the TearCare^®System has not been established in subjects for whom the treatment temperature is lowered from Warmth Level Setting #5 due to patient pain or discomfort.
Do not reuse the SmartLids^™. Cross-contamination can occur if re-use is attempted.
Do not use a TearCare^® System, its components, or accessories that appear damaged. Inspect all components for damage before each use.
The safety and effectiveness of the TearCare^®System is not known in the following patient populations that were excluded in the OLYMPIA pivotal study: patients under 22 years of age, dry eye signs and symptoms other than meibomian gland dysfunction, severe signs and symptoms of dry eye due to meibomian gland dysfunction (OSDI > 79), mild signs and symptoms of dry eye due to meibomian gland dysfunction, and other study exclusions described in the TearCare^®Instructions for Use.

POTENTIAL ADVERSE EVENTS

Potential adverse events may include but are not limited to:

Eyelid or eye pain requiring discontinuation of the treatment procedure
Eyelid irritation or inflammation*
Ocular surface irritation or inflammation*
Ocular symptoms (such as burning, redness, tearing, visual disturbance, redness)
Burn, erythema, or swelling of the eyelids
Conjunctival infection (moderate or severe)
Conjunctival abrasion
Corneal abrasion
Corneal deformation
Allergic or inflammatory reaction to medical adhesive on the SmartLid device
Formation of a chalazion or stye*
Decline in visual acuity*
Worsening of dry eye symptoms*
Increased discomfort or pain of ocular surface (grittiness, foreign body sensation, etc.)
Discomfort or pain of eyelids or orbit*
There is a potential risk of thermal injury to eye or eyelid based on the device design.

Access the Full TearCare Instructions for Use